User profiles for Lucia Baratto
Lucia BarattoMD, Clinical Research Scientist Stanford University Verified email at stanford.edu Cited by 1081 |
Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT
T Nobashi, L Baratto, SA Reddy, S Srinivas… - Clinical nuclear …, 2019 - journals.lww.com
Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and
immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and …
immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and …
[HTML][HTML] Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
…, T Haywood, L Abou-Elkacem, L Baratto… - Nature …, 2019 - nature.com
Advances in precision molecular imaging promise to transform our ability to detect, diagnose
and treat disease. Here, we describe the engineering and validation of a new cystine knot …
and treat disease. Here, we describe the engineering and validation of a new cystine knot …
Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure
Purpose To generate diagnostic 18 F-FDG PET images of pediatric cancer patients from
ultra-low-dose 18 F-FDG PET input images, using a novel artificial intelligence (AI) algorithm. …
ultra-low-dose 18 F-FDG PET input images, using a novel artificial intelligence (AI) algorithm. …
Prostate cancer theranostics targeting gastrin-releasing peptide receptors
Gastrin-releasing peptide receptors (GRPRs), part of the bombesin (BBN) family, are aberrantly
overexpressed in many cancers, including those of the breast, prostate, pancreas, and …
overexpressed in many cancers, including those of the breast, prostate, pancreas, and …
[HTML][HTML] End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision …
…, M Roschewski, KM Walters, CC Chen, L Baratto… - …, 2018 - ncbi.nlm.nih.gov
Dose-adjusted-EPOCH-R obviates the need for radiotherapy in most patients with primary
mediastinal B-cell lymphoma. End-of-treatment PET, however, does not accurately identify …
mediastinal B-cell lymphoma. End-of-treatment PET, however, does not accurately identify …
PSMA-and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical
recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor…
recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor…
[HTML][HTML] 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT
Purpose To evaluate if the new Discovery Molecular Insights (DMI) PET/CT scanner provides
equivalent results compared to the standard of care PET/CT scanners (GE Discovery 600 …
equivalent results compared to the standard of care PET/CT scanners (GE Discovery 600 …
Imaging the distribution of gastrin-releasing peptide receptors in cancer
Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic,
or both diagnostic and therapeutic (theragnostic) purposes is a promising approach in …
or both diagnostic and therapeutic (theragnostic) purposes is a promising approach in …
[HTML][HTML] Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality
Background A newly introduced PET/CT scanner (Discovery Meaningful Insights—DMI, GE
Healthcare) includes the silicon photomultiplier (SiPM) with time-of-flight (TOF) technology …
Healthcare) includes the silicon photomultiplier (SiPM) with time-of-flight (TOF) technology …
Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine …
A Toriihara, L Baratto, T Nobashi, S Park… - European journal of …, 2019 - Springer
Purpose To evaluate the prognostic value of volumetric parameters calculated from 68 Ga-1,4,7,10-tetraazacyclododecane-1,
4, 7, 10-tetraacetic acid (DOTA)-Thr 3 -octreotate ( 68 Ga-…
4, 7, 10-tetraacetic acid (DOTA)-Thr 3 -octreotate ( 68 Ga-…